Key takeaways
- TA836 / TA725 / TA687 NICE technology appraisal numbers for palbociclib, abemaciclib, and ribociclib plus fulvestrant respectively
- 0 head-to-head trials of any CDK4/6 inhibitor plus fulvestrant against exemestane plus everolimus, the pre-CDK4/6i standard of care
- 669 / 726 patients in MONARCH 2 (abemaciclib) and MONALEESA-3 (ribociclib), the pivotal trials underpinning the within-class comparator acceptance
- 9 sheets in the HTA Strategy Model: authority landscape, PICO framework, comparator map, value-dossier tracker, HEOR gap register, economic model params, submission timeline, QC
NICE treats the three CDK4/6 inhibitors as mutually appropriate comparators for each other, but no trial has ever run any of them head-to-head against exemestane plus everolimus, the regimen they displaced.
NICE's technology appraisals for the CDK4/6 inhibitor class in HR+/HER2- advanced breast cancer, TA836 for palbociclib plus fulvestrant, TA725 for abemaciclib plus fulvestrant, and TA687 for ribociclib plus fulvestrant, all treat the class as internally comparable. The committee concluded that abemaciclib plus fulvestrant and ribociclib plus fulvestrant are appropriate comparators for palbociclib plus fulvestrant, drawing on pivotal trials including MONARCH 2 (n=669, abemaciclib) and MONALEESA-3 (n=726, ribociclib). The three drugs share a mechanism but differ in dosing. Palbociclib and ribociclib are once-daily for 21 of a 28-day cycle, while abemaciclib is twice-daily continuously, a PICO-relevant distinction that shapes tolerability comparisons.
The comparator framework has a real gap outside the class itself. No trial directly compares ribociclib plus fulvestrant, or either of its class-mates, against exemestane plus everolimus, the endocrine-based regimen that was standard of care before CDK4/6 inhibitors arrived. That absence matters for any new entrant's HTA submission. NICE's within-class comparator acceptance does not extend automatically to a comparator outside the class, and a submission that assumes it does risks exactly the kind of committee pushback that HEOR teams should price in before the dossier is finalised. Our gap register scores this specific comparator absence by likelihood of being raised and impact if it is, rather than treating every appraisal's evidence base as equally solid.
UK CDK4/6 inhibitor comparator landscape — within-class precedent, and the gap outside it
| Agent | NICE TA | Pivotal Trial | Within-Class Comparator Status |
|---|---|---|---|
| Palbociclib + fulvestrant | TA836 | PALOMA-3 | Reference comparator for the class |
| Abemaciclib + fulvestrant | TA725 | MONARCH 2 (n=669) | Accepted as comparator to palbociclib |
| Ribociclib + fulvestrant | TA687 | MONALEESA-3 (n=726) | Accepted as comparator to palbociclib; no head-to-head vs. exemestane plus everolimus |
Sources: NICE TA836 (palbociclib plus fulvestrant), Committee Discussion; NICE TA725 (abemaciclib plus fulvestrant), Committee Discussion; NICE TA687 (ribociclib plus fulvestrant), Committee Discussion.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- Does NICE's acceptance of within-class comparators (palbociclib vs. ribociclib vs. abemaciclib) extend to comparators outside the class, like exemestane plus everolimus? • NICE's TA836/TA725/TA687 comparator-acceptance precedent • the absent head-to-head evidence against exemestane plus everolimus • the HEOR risk this creates for a new submission
- How should a new HTA submission's PICO framework account for the dosing-schedule differences across the CDK4/6 class? • Once-daily 21/28 (palbociclib, ribociclib) versus continuous twice-daily (abemaciclib) dosing • tolerability-comparison implications • PICO framework construction methodology
- What does the HEOR gap register actually score, and how does that differ from just listing evidence gaps? • Likelihood-times-impact scoring methodology • submission-blocking versus manageable gap classification • the 9-sheet HTA Strategy Model structure
What's inside
-
1 · The Binding Constraint 2 pp
- Why the missing exemestane-plus-everolimus comparator, not the within-class evidence, is the single gap that determines whether the dossier survives challenge
- Pressure-tested against the TA836/TA725/TA687 precedent before the rest of the model is built out
-
2 · HTA Authority Landscape 3 pp
- NICE's technology appraisal process for the CDK4/6 class
- How TA836, TA725, and TA687 relate to each other as precedent
-
3 · PICO Framework 3 pp
- Population, Intervention, Comparator, Outcomes built to NICE's requirements
- Dosing-schedule differences (once-daily 21/28 vs. continuous twice-daily) as a PICO-relevant distinction
-
4 · Comparator Defence 3 pp
- The 3-test comparator defence framework applied to a new CDK4/6-class entrant
- The exemestane-plus-everolimus gap and why it falls outside NICE's within-class precedent
-
5 · Value Dossier Self-Assessment 3 pp
- 5-module, 15-check self-assessment against submission readiness
- Where the dossier is exposed on the exemestane-plus-everolimus question
-
6 · HEOR Gap Register 3 pp
- The comparator gap scored by likelihood of being raised and impact if it is
- Submission-blocking versus manageable classification
-
7 · Economic Model & Submission Timeline 4 pp
- Economic model type selection and benchmark utility values for this class
- Milestone timeline against NICE's appraisal process
-
8 · Client Alignment Questions 2 pp
- The open HEOR questions your team must close before the dossier is finalised
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom model delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this model
AXLRx delivers oncology HTA strategy models built for market access and HEOR teams navigating NICE comparator precedent and evidence gaps. Custom model in 72 hours.
- 1. Submit your requestSpecify your indication, HTA bodies, and comparator scope.
- 2. Scoping callAXLRx analyst confirms comparator set and evidence-gap scope before building.
- 3. DeliveryResearch-verified HTA strategy model in 72 hours with optional analyst readout.
How AXLRx builds this model
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
Every AXLRx HTA strategy model is built from primary HTA-body sources (NICE technology appraisals and committee discussions), not secondary summaries. Every comparator claim is pressure-tested through the 3-test defence framework before being accepted.
UK HR+/HER2- mBC HTA sources: NICE TA836 (palbociclib plus fulvestrant), TA725 (abemaciclib plus fulvestrant), and TA687 (ribociclib plus fulvestrant) committee discussion documents.
- NICE TA836, TA725, and TA687 committee conclusions on within-class comparator acceptance verified against the live NICE guidance pages
- Absence of head-to-head trial evidence against exemestane plus everolimus verified via direct search of the same committee discussion documents
- MONARCH 2 and MONALEESA-3 patient counts verified against the same NICE committee discussion documents
Frequently asked questions
Deliverables What formats are included with every model?
Every commissioned HTA Strategy Model includes an editable 9-sheet Excel model (Cover, HTA Authority Landscape, PICO Framework, Comparator Map, Value Dossier Tracker, HEOR Gap Register, Economic Model Params, Submission Timeline, QC) and a PDF methodology brief — no PowerPoint deck, since an HTA strategy model is built to be worked in directly, not presented from. An optional 45-minute analyst readout call is included.
Sources How is the HTA evidence verified?
AXLRx builds from primary sources only — NICE technology appraisals and committee discussion documents, not secondary summaries. Every comparator claim and evidence gap is independently verified before inclusion.
Customisation Can I scope this to a specific HTA body or comparator set?
Yes. The intake form captures your indication, target HTA bodies, and comparator set. A scoping call confirms scope before research starts. Commission via the intake form to start.